Despite a limited genome size (17, 49) , mycoplasmas have successfully adapted to a wide range of hosts and typically cause persistent infections in humans and animals (23, 39) . Pronounced diversity within mycoplasma species and phenotypic variation in propagating clonal populations have recently been shown to affect the surface architecture of mycoplasmas, predominantly (but not exclusively) involving surface lipoproteins, as reviewed elsewhere (14, 52, 54) . In the absence of cell walls in mycoplasmas, versatility in surface protein structure may be crucial for these organisms to adapt to host niches and to evade host defense mechanisms. Directly or indirectly, highfrequency mutations affecting the expression or structure of genes encoding surface lipoproteins appear to be a major source of this diversification (52, 54) . The molecular basis for surface lipoprotein variation was first elucidated in Vlp proteins of Mycoplasma hyorhinis (8, 57, 58) , and more recently in the pMGA protein of Mycoplasma gallisepticum (30, 31) , the MB antigen of Ureaplasma urealyticum (59) , surface lipoproteins of Mycoplasma fermentans (46) (47) (48) , and the V-1 (Vsa) antigen of Mycoplasma pulmonis (2, 40) . These examples illustrate the complexity of mechanisms in diversification of mycoplasma surface proteins, including (i) size variation caused by gain or loss of intragenic repetitive sequences, (ii) phase switching by deletion/insertion mutations or DNA inversion affecting promoter activity, (iii) differential presentation of expressed surface proteins, and (iv) presence of multigene families or multiple copies of partial genes in the mycoplasmal chromosome (17) , furnishing genetic reservoirs for alternate sequences. Determining the molecular genetic mechanisms of mycoplasma surface variation and adaptation is essential for understanding the mycoplasma-host interaction.
Mycoplasma hominis is associated with human urogenital diseases, pneumonia, and septic arthritis (23) . This species shows extensive population heterogeneity in vitro (4) and possibly in vivo (34) . Previous studies have indicated that surface antigenic profiles of M. hominis are highly heterogeneous among different strains (4, 6, 7, 26, 35) or even among clinical isolates derived longitudinally from a single patient (34) . Although several surface proteins, including P120 (7), P135 (26) , and P50 (19) , have been cloned and characterized, the molecular basis of variation in M. hominis has not been directly established.
In a previous study, a putative adhesin defined by a monoclonal antibody (MAb), H3, that inhibits the metabolism of M. hominis 1620 and blocks attachment of the organism to human fibroblast cells has been described (35) . The component is expressed on the surface of M. hominis and was identified as a lipoprotein on the basis of partitioning characteristics in detergent and metabolic labeling with [ 14 C]palmitate (35) . The antigen recognized by MAb H3 showed variation in size and expression among various M. hominis strains (35) and among isolates derived longitudinally from a single patient (34) . Therefore, the antigen defined by MAb H3 is designated in this paper the variable adherence-associated (Vaa) antigen. Features of Vaa function and variation suggest a possible role in the interaction of M. hominis with the human host. The molecular basis for structural and antigenic variation of the Vaa lipoprotein has not been defined and yet may be critical to our understanding of Vaa in mycoplasmal infection. In this study, alleles of the vaa gene from clonal variants of pathogenic M. hominis 1620 were molecularly cloned and characterized and the basis for two aspects of Vaa variation were defined: (i) size variation caused by gain or loss of central repetitive sequences in the vaa lipoprotein gene and (ii) antigenic variation associated with marked sequence divergence in the distal C-terminal portion of Vaa, compared among additional strains of M. hominis. The role of variation in modulating adherence and/or evading the immune system is discussed.
Construction and immunoblot analysis of recombinant Vaa fusion protein.
To generate a recombinant form of the Vaa antigen, a fragment of the vaa gene representing the N-terminal protein sequence from the Cys residue at position 27 to the Ser residue at position 224 (see Fig. 3 ) was amplified by PCR from pCL1 with primers F4 and R4 (see Fig. 2 ), using Vent polymerase (New England Biolabs) to generate a blunt-ended, high-fidelity PCR product. The PCR product was digested with HindIII to generate a blunt-HindIII fragment, which was gel cleaned with the QIAEX gel extraction kit (QIAGEN) and ligated with XmnIand HindIII-digested pMAL-c2 (New England Biolabs). This created an inframe fusion of the vaa gene to the 3Ј end of the malE gene (confirmed by DNA sequencing), resulting in the expression of a translational fusion with maltosebinding protein (MBP). Since three UGA codons were present near the 3Ј end of this mycoplasmal insert, translation in E. coli would terminate at the first UGA codon encountered (see the boxed Trp at position 207 in Fig. 3 ). Procedures for expression of fusion proteins from the pMAL-c2 vector were performed as specified by the manufacturer. Expressed fusion proteins were affinity purified and analyzed by SDS-PAGE and immunoblotting, with various MAbs or synovial fluids derived from a patient harboring M. hominis 1620 (34) or a patient with rheumatoid arthritis (provided by R. Hoffman, University of Missouri). Immunoblots of human synovial fluids were developed as described for mouse MAbs but with secondary antibody to human immunoglobulin G (Accurate Chemical and Scientific Corp.).
Nucleotide sequence accession numbers. The full sequence of the vaa gene from strain 1620 described in this report (see Fig. 3 ) was deposited in GenBank with accession number U56827. The partial sequence of a vaa gene homolog in strain PG21 was deposited with accession number U56828.
RESULTS
Size variation of the Vaa antigen. By using MAb H3 to examine clonal lineages generated from M. hominis 1620, three size variants of the Vaa antigen were identified and designated Vaa-2, Vaa-3, and Vaa-4. In the original population examined, over 90% of the population of strain 1620 were Vaa-2 variants, expressing a 50-kDa lipoprotein. This was demonstrated by SDS-PAGE analysis of individual colonies. However, a minority of clonal variants expressed larger versions of the antigen, of 78 kDa (Vaa-4) or 64 kDa (Vaa-3) (Fig. 1A to C) . The three Vaa variants partitioned during Triton X-114 (TX-114) phase fractionation into the detergent phase and were specifically recognized by MAb H3 (Fig. 1A) . Vaa antigens were one of the most abundant membrane proteins in M. hominis (Fig. 1E) . Another MAb (A8), previously shown to identify size-variable surface antigens of M. hominis (35) , selectively stained the same size-variant proteins as detected by MAb H3 (Fig. 1B) , strongly suggesting that these two MAbs recognized the same antigen (i.e., lipoprotein) of M. hominis. This finding clarified a previous ambiguity regarding the identity of antigens defined by MAbs H3 and A8 (35) . A third MAb (30.3.1), previously shown to define an M. hominis surface epitope encoded within a cloned DNA fragment (6) , also was shown to specifically recognize the size-variant Vaa antigens (Fig. 1C) . In contrast to these three MAbs, MAbs G5 (Fig. 1D) and 667, 43.2, 552, and 26.7D (data not shown), also directed to M. hominis surface antigens (6, 7, 26) , all stained M. hominis membrane proteins distinct from Vaa.
Cloning and sequencing vaa genes. The plasmid library containing genomic DNA fragments of M. hominis 1620 (Vaa-4) was screened with probe 30.3.1. Two positive recombinant plasmids, designated pCL1 and pCL2 (Fig. 2) , were identified. These two constructs contained mycoplasma DNA inserts of 1.4 kb (pCL1) and 2.5 kb (pCL2), respectively, as determined by restriction analysis. The insert in pCL1 was sequenced by primer walking. The insert in pCL2 (shown below to contain repetitive sequences) was completely sequenced by a strategy of nested deletion ( Fig. 2 ; see Materials and Methods). An intervening genomic region not represented in pCL1 or pCL2 was determined by sequencing cloned PCR products (pCL3) amplified by primer F2 (residing in pCL1) and primer R2 (residing in pCL2) from genomic template DNA of the mycoplasmal isolate expressing Vaa-4. The deduced 716-amino-acid sequence of Vaa-4 reveals an N-terminal signal peptide, consisting of 27 amino acids terminating with the prolipoprotein signal and cleavage site T-I-S-C ( Fig. 3) (3, 10, 44) . This result is consistent with previous biochemical evidence (35) , based on metabolic labeling with palmitate, that Vaa is a lipoprotein. Partitioning of Vaa in the TX-114 detergent phase as an amphiphilic protein is also consistent with a lipoprotein structure, particularly since the entire mature sequence is otherwise predicted to be hydrophilic (24) with predominant alpha-helical characteristics. The calculated molecular mass of the mature Vaa-4 is 79.5 kDa, comparable to the 78 kDa estimated by SDS-PAGE (Fig. 1) . The four tandem repetitive DNA sequences encode periodic peptide structure, accounting for 68% of the Vaa protein sequence from this isolate (Fig. 3) . Each repeat contains 121 amino acids, with a calculated mass of 14 kDa that corresponds to the size difference among the Vaa variants measured by SDS-PAGE ( Fig. 1 ). Repeats contain a high proportion of charged residues; however, the net charge of a repeat is close to neutral. No other ORFs were present on the Vaa coding strand. However, an ORF of 643 amino acids was detected on the opposite strand, spanning most of the Vaa coding region, including repetitive sequences. This ORF contained a potential start codon and ribosome-binding site and was very hydrophobic, with extensive beta-sheet structure.
Gain or loss of intragenic repeats in vaa alleles causes size variation of Vaa. Sequence analysis indicated the presence of TaqI and NciI sites, each closely flanking the ends of the vaa gene (Fig. 2) . To determine the length and copy number of vaa alleles, genomic DNA was extracted from the three clonal lineages (Vaa-2, Vaa-3, and Vaa-4) of strain 1620, completely digested with TaqI or with NciI, and then hybridized with DIG-labeled probe 30.3.1 (Fig. 2) . This probe identified a single NciI-NciI or TaqI-TaqI fragment in the genome of each of these three M. hominis isolates (Fig. 4A) . The sizes of the hybridizing restriction fragments from the clonal lineages expressing size-variant Vaa antigens were approximately 2.1 kb (Vaa-2), 2.5 kb (Vaa-3), and 2.9 kb (Vaa-4), consistent with the fragment sizes predicted from restriction sites identified by sequencing. In addition, the difference in size among the single genomic restriction fragments in each of the three variant lineages was proportional to the predicted size differences (approximately 14 kDa) among the corresponding Vaa proteins in (Fig. 1) . Since the fragment in each variant was not large enough to contain multiple copies of the vaa gene, these results indicated (i) that only one copy of the vaa gene occurs in M. hominis 1620 and (ii) that no reservoir of vaa repeats, other than intragenic copies, occurs in the genome. These results predicted that the size of expressed Vaa lipoprotein should correlate with the length of ORFs encoded by vaa alleles in mycoplasma variants. To confirm this, the entire ORFs encoding size-variant Vaa proteins in the three variants were amplified from genomic DNA by PCR with primers F1 and R1 (Fig. 2) . The PCR products obtained from the three variants were 2.3 kb (Vaa-4), 1.9 kb (Vaa-3), and 1.5 kb (Vaa-2), respectively (Fig. 4B) , consistent with the expression of size-variant proteins. Digestion of the PCR products with HindIII and EcoRI yielded the expected fragments (data not shown), indicating that the PCR products contained specific vaa sequences. The length of a vaa gene corresponded well to the size of the respective Vaa protein expressed by these clonal variants ( Fig. 1 and 4B ).
The precise location of regions responsible for size variation in vaa genes was further confirmed by a PCR strategy with two primers (F2 and R2) closely flanking the internal repetitive region of vaa genes. As shown in Fig. 4B , the sizes of the repeat region in the three clonal lineages were proportional to the sizes of the vaa genes and to the corresponding Vaa proteins. The size differences among the Vaa proteins and among the corresponding vaa alleles were fully accounted for by the size differences contributed by the repeat regions, indicating that the internal repeats alone were responsible for the size variation of the Vaa antigen. PCR products containing the repeat sequences of Vaa-2 and Vaa-3 were also cloned into the pT7blue vector (Novagen) and sequenced. On the basis of sequencing and the sizes of the cloned repeat regions, the three variants were determined to have two (Vaa-2), three (Vaa-3), or four (Vaa-4) internal repeats, respectively.
Structural modules and C-terminal sequence divergence of Vaa antigens. A database search indicated that the Vaa antigen from M. hominis 1620 had regions of significant DNA and protein sequence similarity to P50 (Genbank accession no. X73834), a 50-kDa adhesin previously found in M. hominis FBG (18, 19) . On the basis of this comparison (Fig. 3) , we propose that the P50 product is a variant Vaa antigen expressed in M. hominis FBG. Regions of similarity between these proteins were localized, suggesting the presence of modular features of Vaa antigens, possibly subject to different mechanisms of diversification in the corresponding vaa genes. To simplify comparisons, vaa genes were operationally divided into six regions, as shown in Fig. 5 . The P50 variant of Vaa had an identical signal peptide (region I) and a highly homologous region II compared with Vaa-4 from strain 1620. However, only one unit of the repeat (region III) occurred in P50. This single repeat unit in P50 is similar to that in Vaa-4 but differs by one additional amino acid (residue 153 in Fig. 3 and arrow- Fig. 5 ), which occurred as a result of an additional nucleotide triplet (AGG) in the vaa gene creating a conservative substitution (K 3 R) and an additional in-frame codon. Some repeats in Vaa-2 and Vaa-3 also contained this extra codon (Fig. 5) , showing diversity for this feature even among intragenic repeats in a single variant. Interestingly, the 3Ј repeats in region III of Vaa-2, Vaa-3, and Vaa-4 share a fingerprint of three distinctive nucleotide substitutions (data not shown). In addition to similarity in the N-terminal regions (I, II, and III), the last 10 amino acids at the C-terminal tip (region VI) are identical between the Vaa variants P50 and Vaa-4 ( Fig. 3) . In contrast, striking differences between these two variant proteins occurred within regions IV and V, shown in Fig. 3 and 5. Sequence divergence in region V, near the C terminus, was manifest as nucleotide substitutions and by the presence or absence of short, in-frame oligonucleotide sequences. One region of P50 (indicated as region IV) shares significant but lower homology (69% nucleotide and 53% amino acid identity) with the region III repeat unit, possibly suggesting divergence from a common sequence. These results identified the 3Ј portion of vaa genes as a region of sequence diversity.
To further evaluate the divergence of Vaa sequence among additional M. hominis strains, genomic DNA from M. hominis PG21 (the type strain) was used to generate PCR products representing different portions of the vaa gene. Oligonucleotide primers (Fig. 2) derived from sequences in regions I, II, and III of vaa-4 successfully amplified predicted DNA fragments from strain PG21, whereas primers designed from regions V and VI of vaa-4 failed to yield any PCR products from this strain (data not shown). In addition, a DNA probe containing sequences of regions V and VI of vaa-4 did not hybridize to any genomic DNA fragments of strain PG21 digested with NciI, although probe 30.3.1 identified a single DNA fragment in this strain. To compare the positions of suspected divergence, the 3Ј region of vaa in PG21 was amplified with primers F5 and R1 (Fig. 2) and directly sequenced. It was found that the PG21 version of vaa contained a region IV nearly identical to that of P50 (99% nucleotide and 97% amino acid identity). However, comparison of region V from the three strains revealed significant divergence. For example, sequences in this region showed only 80% nucleotide and 70% amino acid identity between strains 1620 and FBG ( Fig. 5 ; see also Fig. 3) ; 92% nucleotide and 82% amino acid identity between strains PG21 and FBG (Fig. 5) ; and 70% nucleotide and 68% amino acid identity between strains 1620 and PG21 (not indicated in Fig. 5) .
Antigenic variation among Vaa allelic products. A recombinant fusion protein expressed from a malE::vaa fusion (described in Materials and Methods) was used to analyze the locations of specific epitopes by immunoblotting (Fig. 6A1) . This construct contained the N-terminal mature Vaa-4 sequence spanning residues 27 (Cys) to 206 (Ser), including most of the first repeat (Fig. 3) . As expected, MAb 30.3.1 specifically recognized the fusion protein (Fig. 6A1) , because this construct included the sequence of probe 30.3.1 (Fig. 2) , known to encode the epitope recognized by this MAb (6) . MAb H3 also reacted with the fusion protein (Fig. 6A1) , suggesting that the epitope defined by MAb H3 was located in either region II or region III. In contrast, MAb A8 (Fig. 1) and three other MAbs, shown to react with the authentic Vaa protein of strain 1620, did not recognize the truncated recombinant Vaa, suggesting that these MAbs might recognize an epitope involving the more C-terminal portion of Vaa (such as region V beyond the last repeat structure of region III [ Fig. 5]) . Notably, MAb A8 and the three others did not react with any proteins in strain In vivo antibody response to Vaa. M. hominis 1620 was originally isolated from a joint of a patient with septic arthritis (42) and was shown to cause septic arthritis in primates (1). Synovial fluid samples were used to evaluate the in vivo antibody response to the Vaa antigen. One sample (SF 2127) was obtained from the same patient and joint from which M. hominis 1620 was retrieved (34) , and a control sample (SF 9031) was obtained from a patient with rheumatoid arthritis not associated with M. hominis infection (provided by R. Hoffman, University of Missouri). Immunoblotting with SF 2127 revealed a strong immunoglobulin G antibody response to multiple antigens of M. hominis, including the variable Vaa antigen (Fig.  6B1) . Indeed, the Vaa antigen was one of the predominant immunogens of the mycoplasma in this individual. In addition, immunoglobulin G antibodies in SF 2127 recognized the recombinant Vaa (Fig. 6A1) , further confirming that a specific antibody response to Vaa occurred in vivo and was directed, at least in part, to N-terminal or repetitive regions of the lipoprotein. Control SF 9031 showed no antibody to M. hominis antigens or to the Vaa fusion proteins. These results indicate that Vaa is expressed and is highly immunogenic in vivo in an individual with septic M. hominis-associated arthritis.
DISCUSSION
Genetic analysis in this study indicates that Vaa is a lipoprotein with multiple sequence modules subject to mutational variation (Fig. 5) . Immunolabeling with MAb 30.3.1 and H3 previously showed that Vaa is located on the surface of M. hominis (6, 35) . The sequence data reported here, combined with biochemical properties cited, suggest a model for Vaa as a surface lipoprotein anchored to the plasma membrane by lipid covalently bound to an N-terminal cysteine, with alphahelical central repeats and C-terminal regions external of the plasma membrane. This model provides a structural basis to speculate on possible functions associated with domains of the variable Vaa protein. The central repeats could function as a spacer for surface presentation of the C-terminal module, which is a likely adherence-mediating structure of Vaa. In P50 of strain FBG, the adherence-mediating structure has been provisionally mapped to amino acids 390 to 405 (19) , which is located in region V (Fig. 3 and 5 ). Since P50 is considered a variant Vaa protein, it is possible that region V generally contains the adherence module of Vaa. This possibility is consistent with the previous finding that MAb A8, now suspected from our current study to define an epitope in the C-terminal region of Vaa from strain 1620, inhibited adherence of this M. hominis strain (35) . In any case, sequence variability in region V suggests that this portion of the lipoprotein may be under selective pressure in the host. This is consistent both with its location as an external module exposed on the membrane surface and with the putative biological function of Vaa, mediating the interaction of M. hominis with host cells. It should be noted that other means of MAb inhibition might exist. Inhibition of adherence by MAb H3 (35) , recognizing an epitope in region II or III of Vaa, might involve steric hindrance rather than direct binding to the adherence structure. Recombinant constructs representing specific regions or variant Vaa sequences may clarify the role of specific domains in adherence.
The divergent Vaa antigen is a major surface protein of M. hominis (Fig. 1E) and is highly immunogenic in the human host (Fig. 6B1) . The role of Vaa variation in vivo remains to be determined in future studies. It is postulated that variation in region V of Vaa could affect the specificity or affinity of adherence and provide M. hominis with the flexibility to adapt to different niches, such as the urogenital tract, the respiratory tract, or the joints, where distinctive receptors may be required for optimal colonization. There is only limited information on the actual receptor bound by M. hominis. One report suggests that sulfated glycolipids might play this role in the urogenital tract (33) . Any role for Vaa in this interaction has yet to be determined. In addition to modulation of function, C-terminal sequence variation could reflect antigenic drift of Vaa, as illustrated by the lack of MAb A8 binding to the Vaa antigen of strain PG21, in which the C-terminal sequence of Vaa appears to be substantially divergent. Such variation could play a possible protective role, but this has yet to be demonstrated.
Size variation of Vaa caused by a gain or loss of intragenic repetitive sequence could also contribute to the adaptation of (46, 48) . Although additional roles for size variation in M. hominis are speculative, other mycoplasma systems offer possible functions associated with this phenomenon. In the Vlp system of M. hyorhinis for example, convalescent-phase host serum appears to selectively inhibit the growth of organisms expressing smaller Vlp size variants (containing fewer internal repetitive sequences), whereas this serum had no effect on organisms expressing larger Vlp size variants (9) . Repetitive amino acid sequences are present in a number of toxins and surface antigens of pathogenic bacteria (13, 22) . Many of these are ligand-binding proteins and are known or proposed virulence factors, such as M proteins (16, 20) and the fibronectin-binding adhesin of streptococci (45) , RTX toxins of general gram-negative bacteria (50) , lipoprotein H.8 of Neisseria species (21) , and several toxins from clostridia (55) . Repeat structures in these molecules are either directly related to ligand binding, are associated with antigenic variation, or contribute to the overall protein conformation that facilitate pathogen-host interactions (13, 20, 22) . Repetitive sequences are also found in many mycoplasma surface antigens (2, 14, 40, 54, 57, 59) . Homologous recombination and slipped-strand mispairing have been invoked as mechanisms to explain the duplication or exchange of repetitive sequences (28, 36, 41) . Whichever mechanism underlies the contraction or expansion of Vaa repeats, at least two copies of the repeated unit are required. Because only one copy of the vaa gene occurs in the chromosome of M. hominis, the intragenic repeats are the only sources for duplication. This suggests that vaa alleles with only a single repeat unit may fail to undergo further size variation. For example, there is no evidence that P50, with only one repeat unit, shows size heterogeneity (19) . Unlike vaa, several other known mycoplasma adhesin genes, such as the genes encoding the P1 adhesin of Mycoplasma pneumoniae (43) , the MgPa adhesin of Mycoplasma genitalium (11, 17, 29) and the pMGA adhesin of M. gallisepticum (30) , have been shown to occur either as multiple copies of entire genes or as portions of the genes dispersed at different loci on the mycoplasma chromosome. The significance of these redundant repetitive sequences in the diversification of mycoplasmal adhesins has not been clarified, although they could provide genetic reservoirs for DNA rearrangement. It is noteworthy in this context that region V of the Vaa sequence shows diversity through apparent insertion/deletion of small in-frame oligomeric sequences. It is possible that reservoirs of these limited segments are located in other chromosomal locations.
Vaa antigens belong to an important and expanding group of mycoplasmal surface lipoproteins. Prokaryotic lipoproteins are abundant in the periplasmic space and on the surface of gram-negative and gram-positive eubacteria, respectively (3, 44) . They also occur as major membrane surface proteins of mycoplasmas (10, 51, 54 ). An increasing number of diverse biological functions, including substrate binding, protein secretion, signal transduction, and adherence, have been attributed to lipoproteins. Theoretically, membrane-anchored mycoplasma lipoproteins are ideal candidates for executing these biological roles in mycoplasmas, which lack cell walls or other common surface appendages observed in most eubacteria.
Other surface lipoproteins of M. hominis, in addition to Vaa, have been identified (7, 25, 26) . One of these is a 120-kDa protein (P120) defined by MAb 26.7D (7) . P120 has a typical prokaryotic lipoprotein signal peptide and does not have repetitive sequences but possesses hypervariable and semivariable regions, which undergo spontaneous mutations leading to antigenic variation of P120 (5) . The hypervariable region of P120 is near the N terminus of the protein, unlike that in Vaa. The biological function of P120 remains to be determined. Another interesting surface protein is the Lmp1 antigen, a 135-kDa hydrophilic basic surface antigen of M. hominis (26) . Lmp1 appears not to be a lipoprotein, as determined by sequence and biochemical analysis. Although multiple repeats are present in Lmp1, they have not been implicated in the size variation of this protein. Identification and comparison of the genes encoding Vaa lipoprotein adhesins provide new information on the mechanisms of M. hominis diversification. Since the molecular structure and basis of variation of Vaa antigens are known, the possible role of Vaa variation in vivo may now be more directly addressed.
